Table 2.

Tumors were smaller and tumor growth was less in IL-33-deficient vs. WT mice

	WT Veh, n = 12	WT Cis, n = 13	IL-33 Def Veh, n = 9	IL-33 Def Cis, n = 8
Tumor weight, g	0.9 ± 0.07	0.4 ± 0.1*	0.5 ± 0.06	0.2 ± 0.02**
Tumor volume week 1, mm3	9.5 ± 4	1.4 ± 0.5	5 ± 1.8	0.6 ± 0.2
Tumor volume week 2, mm3	55 ± 11	2.7 ± 0.6	30 ± 15+++	2 ± 0.5
Tumor volume week 3, mm3	151 ± 30+	29 ± 14++	43 ± 13+++	4 ± 1.8
Tumor volume week 4, mm3	122 ± 30+	15 ± 9++	33 ± 7+++	4 ± 2.4

Cisplatin completely prevents tumor growth in IL-33-deficient mice.

^*P < 0.001 vs. WT Veh;

^**P < 0.05 vs. IL-33 Def Veh, P < 0.05 vs. WT Cis;

⁺P < 0.01 vs. week 1, P < 0.05 vs. week 2;

⁺⁺P < 0.01 vs. week 1, P < 0.05 vs. week 2, P < 0.01 vs. WT Veh;

⁺⁺⁺P < 0.05 vs. week 1, P < 0.01 vs. WT Veh, P < 0.01 vs. IL-33 Def Cis.